ENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
Read MoreCategory: Speciality
Medacta Showcases Advanced Orthopedic Solutions at ISAKOS
Medacta highlights cutting-edge orthopedic innovations at ISAKOS 2024.
Read MoreEMA Links Semaglutide to Rare Vision Loss Risk
Two-fold increased risk prompts label updates for blockbuster GLP-1 drugs.
Read MoreJ&J Faces $442M Treble Damages Over Catheter Monopoly
J&J’s $147M antitrust penalty tripled to $442M for monopolizing cardiac catheter market.
Read MoreInnovent’s IBI363 Gains Second China BTD for Resistant Lung Cancer
China’s National Medical Products Administration has granted a second Breakthrough Therapy Designation to Innovent Biologics’ IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating...
Read More